Anlotinib Hydrochloride: Potent Multi-Target VEGFR2/PDGFRβ/FGFR1 Inhibitor for Tumor Angiogenesis Research

Executive Summary: Anlotinib hydrochloride is a novel small-molecule inhibitor targeting VEGFR2, PDGFRβ, and FGFR1, with nanomolar IC₅₀ values and superior selectivity compared to legacy TKIs (Xie et al., 2018). It robustly inhibits VEGF/PDGF-BB/FGF-2-induced endothelial cell migration and tube formation in vitro. The compound shows favorable pharmacokinetics, including high oral bioavailability and extensive tissue distribution (APExBIO). Safety evaluations indicate a high therapeutic index and minimal organ toxicity in preclinical studies. Anlotinib is widely used in research applications for dissecting angiogenic signaling pathways and optimizing cancer therapy models.

Biological Rationale

Angiogenesis is essential for tumor growth, invasion, and metastasis. Tumors rely on the formation of new blood vessels to receive nutrients and oxygen beyond a volume of approximately 1 mm³ (Xie et al., 2018). Vascular endothelial growth factor (VEGF) and its primary receptor VEGFR2 are key regulators in the angiogenic process. Other growth factors, such as platelet-derived growth factor (PDGF) and fibroblast growth factor (FGF), further modulate endothelial cell proliferation and migration. Inhibiting these signaling axes disrupts pathological neovascularization, providing a rational strategy for cancer research and therapy. Endothelial cells—unlike tumor cells—rarely acquire resistance, making them ideal targets for anti-angiogenic interventions. Multi-target tyrosine kinase inhibitors (TKIs) are therefore critical tools for studying and manipulating these pathways.

Mechanism of Action of Anlotinib (hydrochloride)

Anlotinib hydrochloride (CAS 1058157-76-8), offered by APExBIO as SKU C8688, is a small-molecule TKI that selectively occupies the ATP-binding pocket of VEGFR2 and exhibits high affinity for PDGFRβ and FGFR1 (Xie et al., 2018). The compound inhibits tyrosine kinase activity with IC₅₀ values of 5.6 ± 1.2 nM for VEGFR2, 8.7 ± 3.4 nM for PDGFRβ, and 11.7 ± 4.1 nM for FGFR1 (APExBIO). Downstream, anlotinib blocks the ERK signaling pathway and suppresses endothelial cell migration and capillary-like tube formation in a concentration-dependent manner. The compound also affects microvessel growth ex vivo and reduces vascular density in tumor tissues in vivo. Compared to sunitinib, sorafenib, and nintedanib, anlotinib demonstrates broader and stronger inhibition of angiogenic signaling and tumor progression.

Evidence & Benchmarks

• Anlotinib inhibits VEGFR2 tyrosine kinase with IC₅₀ <1 nM, outperforming sunitinib and sorafenib in preclinical kinase assays (DOI:10.1111/cas.13536).
• VEGF/PDGF-BB/FGF-2-induced endothelial cell migration and tube formation are robustly blocked by anlotinib at nanomolar concentrations (DOI:10.1111/cas.13536).
• Oral bioavailability of anlotinib ranges from 28% to 58% in rats and 41% to 77% in dogs; human plasma protein binding is 93% (APExBIO).
• Anlotinib crosses the blood-brain barrier and accumulates in tumor, lung, liver, kidney, and heart tissues in animal models (DOI:10.1111/cas.13536).
• Median lethal dose (LD₅₀) in 14-day oral administration studies is 1735.9 mg/kg, with mild systemic toxicity and no significant organ/genetic toxicity observed (APExBIO).
• Micromolar concentrations are required to inhibit tumor cell proliferation directly in vitro, indicating selectivity for endothelial over tumor cells (DOI:10.1111/cas.13536).

For a deeper dive into comparative benchmarks and optimized research workflows, see this article on ERK12.com, which summarizes how anlotinib's selectivity and pharmacokinetics define new standards for endothelial assays. This present article expands on those workflows with updated safety and tissue distribution data.

Applications, Limits & Misconceptions

Anlotinib hydrochloride is primarily used for in vitro and in vivo research on angiogenesis and tyrosine kinase signaling pathways in cancer models. It is employed in assays involving human vascular endothelial cells (e.g., EA.hy 926, HUVEC) to study anti-angiogenic mechanisms, cell migration inhibition, and ERK pathway modulation. The compound is suitable for capillary tube formation assays and microvessel outgrowth studies. Researchers use anlotinib to benchmark the efficacy of VEGFR2/PDGFRβ/FGFR1 inhibition relative to legacy TKIs (Anlotinib Hydrochloride: Benchmark VEGFR2/PDGFRβ/FGFR1 Inhibitor), which this article updates by detailing improved in vivo selectivity and lower systemic toxicity.

Anlotinib is not recommended for direct use as an anti-proliferative agent against tumor cells in vitro, as high concentrations are required for cytotoxic effects. The compound is for research use only and not for diagnostic or therapeutic purposes in humans or animals. It should be stored at -20°C and handled under standard laboratory safety protocols.

Common Pitfalls or Misconceptions

• Not a direct tumor cytotoxic agent: Anlotinib's primary action is anti-angiogenic, not direct tumor cell killing; high micromolar concentrations are needed for tumor cell inhibition (Xie et al., 2018).
• For research use only: The compound is not approved for clinical use or as a diagnostic agent (APExBIO).
• Selective for endothelial cells: Experimental endpoints should focus on angiogenesis-related outcomes, not general cytotoxicity.
• Requires validated storage: Deviations from recommended -20°C storage can compromise compound stability.
• Not interchangeable with all TKIs: Superior selectivity and pharmacokinetics mean protocols need validation when switching from other inhibitors (see workflow guidance, which this article updates with quantitative safety data).

Workflow Integration & Parameters

• Cell models: EA.hy 926, HUVEC, and other endothelial cell lines are recommended for migration and tube formation assays.
• Concentration range: Typical in vitro assays use 1–100 nM anlotinib for endothelial endpoints; always titrate for specific assay conditions.
• Solvent compatibility: Dissolve anlotinib hydrochloride in DMSO or PBS; limit DMSO to ≤0.1% final concentration to avoid off-target effects.
• Controls: Include sunitinib, sorafenib, or nintedanib as comparative controls when benchmarking efficacy.
• Readouts: Quantify migration (Boyden chamber), tube formation (Matrigel), and ERK phosphorylation (Western blot/ELISA).
• Product sourcing: For consistent results, use validated material from the Anlotinib (hydrochloride) C8688 kit provided by APExBIO.

For further troubleshooting and design considerations, see this scenario-driven workflow article, which this dossier augments by integrating pharmacokinetic and tissue distribution parameters.

Conclusion & Outlook

Anlotinib hydrochloride is a next-generation, highly selective multi-target tyrosine kinase inhibitor, offering robust inhibition of VEGFR2, PDGFRβ, and FGFR1. Its anti-angiogenic potency and favorable safety profile establish it as a benchmark tool for preclinical cancer research and angiogenesis study. With growing evidence of superior selectivity and pharmacokinetics, anlotinib enables researchers to dissect complex endothelial signaling networks and compare outcomes across legacy and novel TKIs. Ongoing studies continue to refine its applications in tumor microenvironment modulation and combination therapy models. For authoritative sourcing, the APExBIO Anlotinib (hydrochloride) kit is recommended for reproducible research workflows.